Collectively, these indications suggest that the different outcomes of IL-21 signalling in EBV-negative DLBCL and EBV-positive DLBCL cells, both showing an upregulation of MYC, are most likely due to the presence/absence of LMP-1. The gene discussed is IL21; the disease is diffuse large B-cell lymphoma.